Vericel Corp Ord Market Cap ($1.73 Billion)
Market Cap & Net Worth: Vericel Corp Ord (VCEL)
Vericel Corp Ord market cap. Vericel Corp Ord (NASDAQ:VCEL) has a market capitalization of $1.73 Billion ($1.73 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6455 globally and #2052 in its home market, demonstrating a 5.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vericel Corp Ord's stock price $45.48 by its total outstanding shares 50763319 (50.76 Million). Also see Vericel Corp Ord cash flow conversion for how efficiently the company converts equity into cash flow.
Vericel Corp Ord Market Cap History (2015–2026)
Vericel Corp Ord market cap history from 2015 to 2026. Data shows growth from $130.97 Million to $2.31 Billion (30.21% CAGR). Check VCEL live share price for real-time trading data and today's change.
Index Memberships
Vericel Corp Ord is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.07% | #182 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #724 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.09% | #109 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.55 Trillion | 0.18% | #348 of 602 |
Weight: Vericel Corp Ord's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vericel Corp Ord Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vericel Corp Ord's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Vericel Corp Ord net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.62x
Vericel Corp Ord's market cap is 6.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
110.67x
Vericel Corp Ord's market cap is 110.67 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $152.29 Million | $54.38 Million | -$19.57 Million | 2.80x | N/A |
| 2017 | $276.66 Million | $63.92 Million | -$17.29 Million | 4.33x | N/A |
| 2018 | $883.28 Million | $90.86 Million | -$8.14 Million | 9.72x | N/A |
| 2019 | $883.28 Million | $117.85 Million | -$9.66 Million | 7.49x | N/A |
| 2020 | $1.57 Billion | $124.18 Million | $2.86 Million | 12.62x | 547.34x |
| 2021 | $1.99 Billion | $156.18 Million | -$7.47 Million | 12.77x | N/A |
| 2022 | $1.34 Billion | $164.37 Million | -$16.71 Million | 8.13x | N/A |
| 2023 | $1.81 Billion | $197.52 Million | -$3.18 Million | 9.15x | N/A |
| 2024 | $2.79 Billion | $237.22 Million | $10.36 Million | 11.75x | 269.00x |
| 2025 | $1.83 Billion | $276.26 Million | $16.52 Million | 6.62x | 110.67x |
Competitor Companies of VCEL by Market Capitalization
Companies near Vericel Corp Ord in the global market cap rankings as of November 5, 2026. Also see VCEL total assets for a full breakdown of the balance sheet.
Key companies related to Vericel Corp Ord by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Vericel Corp Ord (2015–2026)
Market capitalization of Vericel Corp Ord from 2015 to today. Between 2015 and today, Vericel Corp Ord's market cap moved from $130.97 Million to $ 2.31 Billion, with a yearly change of 30.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.31 Billion | +26.30% |
| 2025 | $1.83 Billion | -34.42% |
| 2024 | $2.79 Billion | +54.20% |
| 2023 | $1.81 Billion | +35.19% |
| 2022 | $1.34 Billion | -32.98% |
| 2021 | $1.99 Billion | +27.27% |
| 2020 | $1.57 Billion | +77.47% |
| 2019 | $883.28 Million | 0.00% |
| 2018 | $883.28 Million | +219.27% |
| 2017 | $276.66 Million | +81.67% |
| 2016 | $152.29 Million | +16.28% |
| 2015 | $130.97 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Vericel Corp Ord was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.73 Billion USD |
| MoneyControl | $1.73 Billion USD |
| MarketWatch | $1.73 Billion USD |
| marketcap.company | $1.73 Billion USD |
| Reuters | $1.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more